Imagine a world where your local hospital runs out of basic antibiotics, and the only country making them refuses to ship more. It isn't a sci-fi plot. It's the current reality of our medical supply chain. But while Washington has spent years panicking over basic generic drugs, a much bigger threat has been quietly developing right under our noses.
We aren't just losing the battle over raw ingredients anymore. We're actively financing China's state-backed plan to dominate the next generation of life-saving medicines.
House Select Committee on China Chairman John Moolenaar dropped a political bombshell by sending an urgent letter to Treasury Secretary Scott Bessent. The demand? Treat biotechnology as a prohibited technology under the Comprehensive Outbound Investment National Security (COINS) Act. Moolenaar didn't mince words. He warned that the US is locked in a fierce biotech competition with the Chinese Communist Party (CCP), and American capital is fueling our opponent's rapid climb up the pharmaceutical ladder.
If you think this is just standard political theater, the numbers say otherwise. We're handing over our intellectual property, our cash, and our competitive edge to a strategic adversary. And we're doing it willingly.
The Massive Inflow of American Dollars
For decades, the US has been the undisputed king of biotech innovation. If you wanted to develop a breakthrough cancer therapy or a cutting-edge biologic, you did it in America. But over the last few years, a terrifying shift occurred.
Look at the data from the Select Committee. In 2020, Chinese companies were involved in literally 0% of major global drug licensing deals worth $50 million or more. Fast forward to last year, and that number skyrocketed to 48%. Think about that for a second. Nearly half of the world's major pharmaceutical licensing deals are now inked with Chinese firms.
Cross-border out-licensing transactions between multinational pharma giants and Chinese biotech firms hit a staggering $136 billion. A prime example is Bristol Myers Squibb's recent $15 billion mega-deal with China's Hengrui Pharma. This isn't just cash moving across borders. It is a massive transfer of commercialization know-how and intellectual property straight to Chinese entities.
US pharma companies are looking for quick, cheap wins to pad their pipelines. They lack the long-term vision to see that they're funding their own obsolescence. By buying up Chinese drug assets, American companies are starving local preclinical startups of the capital they need to survive.
Moving Up the Value Chain
China's playbook isn't new. They used the exact same strategy to corner the market on solar panels, rare earth elements, electric vehicle batteries, and steel. First, you use heavy state subsidies to build massive infrastructure. Next, you undercut global prices to drive international competitors out of business. Finally, when you control the supply chain, you start dictating the rules.
Rep. Neal Dunn, a physician who spent 35 years practicing medicine before joining Congress, laid it out perfectly during a committee hearing. He noted that in 2014, China ran fewer than 2,000 clinical trials. By 2023, that number exploded to over 11,000. You don't build a massive clinical trial infrastructure like that by accident. You do it by state-directed design.
Beijing wants to replace American pharma, not just supply it. They've already locked down the basics.
- 90% of the generic drugs Americans take rely on active pharmaceutical ingredients (APIs) from China.
- 90% of the global supply for generic antibiotics flows through Chinese factories.
- 100% of the global processing for Heparin, a critical blood thinner used in every major hospital, happens in China.
If a military conflict breaks out over Taiwan, or if Beijing decides to impose strict export controls, American patients will suffer immediately. It isn't a trade dispute. It's a national security emergency.
Washington's Belated Crackdown
The federal government is finally waking up to the danger, but the political infighting isn't helping. The House Appropriations Committee recently issued a draft spending bill that would outright block the FDA from accepting clinical data generated in adversarial nations like China. Lawmakers are explicitly calling early-phase trials in China a form of "transferring know-how to our adversary."
At the same time, the regulatory landscape inside the US is a mess. Ranking Member Ro Khanna raised valid alarms about self-inflicted wounds to American research infrastructure. Recent political moves have gutted federal scientific agencies, forcing out thousands of career staff at the National Institutes of Health (NIH) and the FDA. The NIH funded roughly 59% of all new drug approvals in the US between 2000 and 2023. Cutting those budgets shrinks our internal pipeline exactly when China is ramping theirs up.
The private sector is starting to feel the squeeze from both sides. For smaller American biotechs, sourcing assets from China has become a legal and financial minefield. Due diligence costs are soaring. There's a growing fear that if a Chinese partner generates negative or sloppy data during a regional clinical trial, it could tank the value of the American company's entire global investment.
The Immediate Steps Forward
We're running out of time to fix this mess. National security experts estimate the US has a very narrow window to retain its biotech primacy before China takes an unassailable lead. Passing the COINS Act and blocking outbound capital from flowing into Chinese biotech is a necessary first step, but restriction alone won't save American innovation.
We need an aggressive domestic strategy. Congress must immediately restore and protect funding for the NIH and FDA to speed up domestic drug discovery platforms and clinical R&D capabilities. Tax incentives must be deployed to lure biologics manufacturing back to US soil, or at least to friendly allied nations.
Biopharma executives need to stop chasing cheap short-term licensing deals in Shanghai and start reinvesting in American preclinical companies. Relying on an adversarial state for the future of medicine is a gamble we're guaranteed to lose.
